血しょう分画製剤の安全性に関する検討　　Ｉ．　モノクローナル抗体精製乾燥濃縮人血液凝固第ＶＩＩＩ因子製剤（クロスエイトＭ）の製造工程におけるウイルスの不活化／除去効果について

DOI

書誌事項

タイトル別名
  • Viral Safety of Plasma-derived Blood Products. I. Efficiency of Virus Inactivation/Elimination during Manufacturing Process of Monoclonal Antibody-purified Freeze-Dried Coagulation Factor VIII Concentrate(CROSS EIGHT M).
  • I. Efficiency of Virus Inactivation/Elimination during Manufacturing Process of Monoclonal Antibody-purified Freeze-Dried Coagulation Factor VIII Concentrate (CROSS EIGHT M<sup>®</sup>)
  • I. モノクローナル抗体精製乾燥濃縮人血液凝固第VIII因子製剤 (クロスエイトM<sup>®</sup>) の製造工程におけるウイルスの不活化/除去効果について

この論文をさがす

説明

CROSS EIGHT M® is a monoclonal antibody-purified factor VIII concentrate produced by the Japanese Red Cross from donated blood plasma. During its manufacture, viruses are expected to be inactivated and eliminated by either solvent/detergent (S/D) treatment or both immunoaffinity and anion exchange chromatography.<br>To validate virus inactivation/elimination during the manufacture of CROSS EIGHT M®, the amount of virus spiked in the manufacturing materials was measured before and after treatment, and the efficiency of virus clearance was calculated for each step. The viruses used were as follows: sindbis virus (SIN), vesicular stomatitis virus (VSV), human immunodeficiency virus type 1 (HIV-1), hepatitis B virus (HBV) and herpes simplex virus type 1(HSV-1) as enveloped viruses; and hepatitis A virus (HAV) and polio virus (Polio V) as non-enveloped viruses.<br>The result shows that enveloped viruses were effectively inactivated to below detection level after S/D treatment with logarithmic reduction values (LRVs) of 5.6 in SIN, >4.4 in VSV, >5.2 in HSV-1 and >4.9 in HIV-1. In contrast, non-enveloped viruses were not inactivated by S/D treatment. Using the immunoaffinity chromatography process, both enveloped and non-enveloped viruses were eliminated with the LRVs of >3.1 in polio V, >5.4 in VSV, >4.4 in SIN, 4.5 in HAV and 5.4 in HBV. LRVs with anion exchange chromatography varied among viruses, from 0 in HAV to 1.9 in Polio V, depending on the condition of the viral particles.

収録刊行物

  • 日本輸血学会雑誌

    日本輸血学会雑誌 45 (3), 349-356, 1999

    一般社団法人 日本輸血・細胞治療学会

キーワード

詳細情報 詳細情報について

  • CRID
    1390282679885442816
  • NII論文ID
    130003706998
  • DOI
    10.3925/jjtc1958.45.349
  • ISSN
    18838383
    05461448
  • 本文言語コード
    ja
  • データソース種別
    • JaLC
    • Crossref
    • CiNii Articles
  • 抄録ライセンスフラグ
    使用不可

問題の指摘

ページトップへ